Author/Authors :
Alizadeh Bahmani, Amir Hossein Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran , Hoorang, Mehdi Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran , Hosseini, Sheida Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran , Eskandari, Mehrnoosh Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran , Shayestehfard, Kiana Department of Pharmaceutical Biotechnology - Shiraz University of Medical Sciences, Shiraz, Iran , Shekoohi, Mahyar Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran , Hatami-Mazinani. Nazafarin Department of Clinical Pharmacy - Shiraz University of Medical Sciences, Shiraz, Iran , Afifi, Saba Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran , Sabzghabaee. Ali Mohammad Isfahan Clinical Toxicology Research Center - Isfahan University of Medical Sciences, Isfahan, Iran , Peymani, Payam Health Policy Research Center - Institute of Health - Shiraz University of Medical Sciences, Shiraz, Iran
Abstract :
Coronavirus 19 (COVID-19) is an extremely transmittable microbial infection that has emerged in Wuhan (China) in late 2019, leading to severe acute respiratory syndrome coronavirus 2 syndrome, and caused a pandemic all over the globe. This study is a systematic review of all 927 clinical trial studies performed worldwide from the beginning of the COVID-19 mysterious pandemic in China. These researches have registered in different databases. According to the best of our knowledge, China (74.82%), the United States (4.49%), and France (2.72%) have the most significant number of clinical trials, respectively. Clinical trials can be randomized or nonrandomized. Due to our results, 32.58% of studies were randomized, and 7.12% were not randomized. Most of the studies were open‑labeled studies (22.44%), and double‑blinded (4.42%) and quadruple blinded (2.48%) studies stand in second and third place regarding the number of trials, respectively. The direction and quantity of clinical trials attempted to identify a possible cure for COVID-19 demonstrates the depth of this crisis. As we are writing this article, a significant international endeavor will find a cure or vaccine for containing this devastating and mysterious disease.
Keywords :
2019-novel coronavirus , clinical trials , severe acute respiratory syndrome-coronavirus 2 , review , outcome , clinical trials , 2019-novel coronavirus
